GlassScriptPhysician profile
Luis G Valle
NPI 1790949667
$1,996.52
in general payments reported to CMS, 2019-2025
33 companies · $23.81 in 2025
The $23.81 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $86.95 · 2021: $298 · 2022: $331 · 2023: $242 · 2024: $703 · 2025: $23.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $320.42 | 2019-2024 | Rexulti, Nuedexta, Abilify Mycite |
| Novo Nordisk INC | $298.74 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Alkermes, INC. | $205.08 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $108.38 | 2019-2024 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $99.20 | 2021 | |
| Vanda Pharmaceuticals INC. | $91.98 | 2019-2024 | Fanapt |
| Janssen Pharmaceuticals, INC | $91.00 | 2019-2024 | Spravato |
| Pfizer INC. | $61.47 | 2019-2023 | |
| Axsome Therapeutics, INC. | $57.10 | 2022-2023 | Auvelity |
| Abbvie INC. | $54.03 | 2022-2024 | |
| Abbott Laboratories | $48.56 | 2024-2025 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $46.48 | 2021 | |
| Scilex Pharmaceuticals INC. | $44.79 | 2024 | |
| Gilead Sciences, INC. | $42.99 | 2023-2024 | |
| Averitas Pharma INC. | $42.53 | 2024 | Qutenza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $38.57 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Lundbeck LLC | $38.07 | 2024 | Rexulti |
| Amgen INC. | $35.69 | 2021-2022 | |
| Glaxosmithkline, LLC. | $31.94 | 2023-2024 | Trelegy Ellipta |
| Corium, LLC | $28.97 | 2024 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.43 | 2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $19.74 | 2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $19.11 | 2024 | Austedo Xr |
| Exact Sciences Corporation | $16.53 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.79 | 2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $15.49 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $15.46 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.20 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.95 | 2024 | Airsupra |
| Mylan Specialty L.P. | $14.45 | 2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $12.81 | 2022 | |
| Grt US Holding, INC. | $12.63 | 2022 | |
| Indivior INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Valle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.